Expression of vascular endothelial growth factor receptor in thymic epithelial tumors

Chiba,Kensuke; Murase,Takayuki; Yokota,Keisuke; Tatematsu,Tsutomu; Oda,Risa; Nakamura,Ryuji; Yobita,Shogo; Takano,Takatsugu; Okuda,Katsuhiro

doi:10.3892/ol.2024.14516

Expression of vascular endothelial growth factor receptor in thymic epithelial tumors

Authors:
- Kensuke Chiba
- Takayuki Murase
- Keisuke Yokota
- Tsutomu Tatematsu
- Risa Oda
- Ryuji Nakamura
- Shogo Yobita
- Takatsugu Takano
- Katsuhiro Okuda
View Affiliations

Affiliations: Department of Thoracic and Pediatric Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan, Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: June 18, 2024 https://doi.org/10.3892/ol.2024.14516
Article Number: 383
Copyright: © Chiba et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymic epithelial tumors (TETs) are rare and the major symptoms are not obvious until the tumor progresses to a relatively large size and compresses the surrounding organs. As its growth is aggressive and it metastasizes to distant organs, it is important to find novel effective therapies. Lenvatinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is approved as a drug therapy for thymic carcinoma (TC); however, although it is a molecular targeted therapy, there are no obvious predictors of therapeutic efficacy. The present study aimed to assess the association between clinicopathological factors and the protein expression of VEGFR, which is associated with tumor aggressiveness and the efficacy of VEGFR inhibitors. The VEGFR‑2 protein expression was evaluated in 144 patients with TETs who underwent surgical resection. The present study assessed whether the expression of VEGFR‑2 protein was associated with TET classification and pathological stage, progression‑free survival and overall survival (OS). A total of 94 cases (65.2%) were positive for VEGFR‑2 protein. The expression of VEGFR‑2 was higher in the more aggressive type B3 thymoma and TC (88.5%) than in types A, AB, B1 and B2 thymoma (60.2%). The 5‑year OS rate for the overall population was 53.1%. The 5‑year OS rates of patients with negative VEGFR‑2 staining score values (66.5%) were significantly longer than in patients with positive VEGFR‑2 staining score values (42.5%; P=0.000078). Furthermore, the pathological stage was the only factor significantly associated with OS in multivariate analysis. The results of the present study suggest the possibility that the indications for VEGF inhibitor therapy could be extended to type B3 thymoma.

View Figures

View References

1	Girard N, Ruffini E, Marx A, Faivre-Finn C and Peters S; ESMO Guidelines Committee, : Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 (Suppl 5):v40–v55. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, et al: Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): A multicentre, phase 2 trial. Lancet Oncol. 21:843–850. 2020. View Article : Google Scholar : PubMed/NCBI
3	Zhu C, Ma X, Hu Y, Guo L, Chen B, Shen K and Xiao Y: Safety and efficacy profile of lenvatinib in cancer therapy: A systematic review and meta-analysis. Oncotarget. 7:44545–44557. 2016. View Article : Google Scholar : PubMed/NCBI
4	Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al: Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 8:831–840. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ellis LM and Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
6	Cimpean AM, Marius R, Svetlana E, Cornea R and Viorica B: Immunohistochemical expression of vascular endothelial growth factor A (VEGF) and its receptors (VEGFR1, 2) in normal and pathologic conditions of human thymus. Ann Anat. 190:238–245. 2008. View Article : Google Scholar : PubMed/NCBI
7	WHO classification of tumours editorial board, . International agency for research on cancer: Thoracic Tumours. 5th Edition. Lyon; France: 2021
8	Brierley JD, Gospodarowicz MK and Wittekind C: The TNM classification of malignant tumors. 8th Edition. Wiley Blackwell; Oxford: 2017
9	Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 142:1364–1382. 2018. View Article : Google Scholar : PubMed/NCBI
10	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
11	Imbimbo M, Vitali M, Fabbri A, Ottaviano M, Pasello G, Petrini I, Palmieri G, Berardi R, Zucali P, Ganzinelli M, et al: RELEVENT trial: Phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma/B3 thymoma with area of carcinoma. Clin Lung Cancer. 19:e811–e814. 2018. View Article : Google Scholar : PubMed/NCBI
12	Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, et al: A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 46:844–849. 2014. View Article : Google Scholar : PubMed/NCBI
13	Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, et al: A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 22:44–53. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, et al: Early changes in circulating FGF19 and ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel). 12:2932020. View Article : Google Scholar : PubMed/NCBI
15	Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, et al: Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 75:213–221. 2017. View Article : Google Scholar : PubMed/NCBI
16	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar : PubMed/NCBI
17	Dvorak HF, Brown LF, Detmar M and Dovrak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1029–1039. 1995.PubMed/NCBI
18	Mustonen T and Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 129:895–898. 1995. View Article : Google Scholar : PubMed/NCBI
19	Ferrara N, Houck K, Jakeman L and Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 13:18–32. 1992. View Article : Google Scholar : PubMed/NCBI
20	Luo JC, Yamaguchi S, Shinkai A, Shitara K and Shibuya M: Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 58:2652–2660. 1998.PubMed/NCBI
21	Detterbeck F, Youssef S, Ruffini E and Okumura M: A review of prognostic factors in thymic malignancies. J Thorac Oncol. 6 (7 Suppl 3):S1698–S1704. 2011. View Article : Google Scholar : PubMed/NCBI
22	Asamura H, Nakagawa K, Matsuno Y, Suzuki K, Watanabe S and Tsuchiya R: Thymoma needs a new staging system. Interact Cardiovasc Thorac Surg. 3:163–167. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H and Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 78:1379–1384. 1998. View Article : Google Scholar : PubMed/NCBI
24	Ichikura T, Tomimatsu S, Ohkura E and Mochizuki H: Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol. 78:132–137. 2001. View Article : Google Scholar : PubMed/NCBI
25	Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD and West CM: Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 83:620–625. 2000. View Article : Google Scholar : PubMed/NCBI
26	Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plénat F, Leclère J, Duprez A and Weryha G: Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 86:656–658. 2001. View Article : Google Scholar : PubMed/NCBI
27	Hsueh C, Lin JD, Wu IC, Chao TC, Yu JS, Liou MJ and Yeh CJ: Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol. 103:395–399. 2011. View Article : Google Scholar : PubMed/NCBI